| 000 | 01804 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516081059.0 | ||
| 264 | 0 | _c20130318 | |
| 008 | 201303s 0 0 eng d | ||
| 022 | _a1399-3003 | ||
| 024 | 7 |
_a10.1183/09031936.00137511 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSimonneau, Gérald | |
| 245 | 0 | 0 |
_aSelexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. _h[electronic resource] |
| 260 |
_bThe European respiratory journal _cOct 2012 |
||
| 300 |
_a874-80 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAcetamides _xtherapeutic use |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aFamilial Primary Pulmonary Hypertension |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrazines _xtherapeutic use |
| 650 | 0 | 4 | _aReceptors, Epoprostenol |
| 650 | 0 | 4 |
_aReceptors, Prostaglandin _xagonists |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
| 650 | 0 | 4 |
_aVasodilator Agents _xtherapeutic use |
| 700 | 1 | _aTorbicki, Adam | |
| 700 | 1 | _aHoeper, Marius M | |
| 700 | 1 | _aDelcroix, Marion | |
| 700 | 1 | _aKarlócai, Kristóf | |
| 700 | 1 | _aGaliè, Nazzareno | |
| 700 | 1 | _aDegano, Bruno | |
| 700 | 1 | _aBonderman, Diana | |
| 700 | 1 | _aKurzyna, Marcin | |
| 700 | 1 | _aEfficace, Michela | |
| 700 | 1 | _aGiorgino, Ruben | |
| 700 | 1 | _aLang, Irene M | |
| 773 | 0 |
_tThe European respiratory journal _gvol. 40 _gno. 4 _gp. 874-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1183/09031936.00137511 _zAvailable from publisher's website |
| 999 |
_c21571937 _d21571937 |
||